Recently, the serine threonine kinase (STK) activity profiles in PBMCs from a small group of 28 metastatic NSCLC patients treated with nivolumab as well as healthy individuals were reported.10 Baseline activity of the CAMK family and AGC family was higher in the group of patients with relatively lower survival after PD-1 blockade when compared with patients with longer survival or healthy individuals. Here, PDCD1 is linked to non-small cell lung carcinoma.